{"filing":{"accession_number":"0001193125-26-329528","cik":"0002042347","ticker":"SPTX","company_name":"Seaport Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"sptx-20260803.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526329528/sptx-20260803.htm"},"events":[{"id":23316,"run_id":21084,"accession_number":"0001193125-26-329528","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release for Q2 2026 filed under Item 2.02. The press release (Exhibit 99.1) discloses quarterly financial results including R\u0026D expenses ($24.6M), G\u0026A expenses ($41.2M), net loss ($62.6M), and cash position ($427.3M), along with clinical and corporate progress updates. The filing explicitly states the press release is being furnished as Exhibit 99.1 in connection with the announcement of financial results for the quarter ended June 30, 2026.","company_name":"Seaport Therapeutics, Inc.","ticker":"SPTX","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23513,"accession_number":"0001193125-26-329528","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q2 2026 filed under Item 2.02. The press release (Exhibit 99.1) discloses quarterly financial results including R\u0026D expenses ($24.6M), G\u0026A expenses ($41.2M), net loss ($62.6M), and cash position ($427.3M), along with clinical and corporate progress updates. The filing explicitly states the press release is being furnished as Exhibit 99.1 in connection with the announcement of financial results for the quarter ended June 30, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:19:17.604888+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23513,"accession_number":"0001193125-26-329528","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q2 2026 filed under Item 2.02. The press release (Exhibit 99.1) discloses quarterly financial results including R\u0026D expenses ($24.6M), G\u0026A expenses ($41.2M), net loss ($62.6M), and cash position ($427.3M), along with clinical and corporate progress updates. The filing explicitly states the press release is being furnished as Exhibit 99.1 in connection with the announcement of financial results for the quarter ended June 30, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:19:17.604888+00:00","company_name":"Seaport Therapeutics, Inc.","ticker":"SPTX","filing_date":"2026-08-03"}]}